Loading...
Freedom of Information (FOI) NHS Lothian | Our Organisation

Request and Response Register

NOTE: 100 recent requests are displayed below. Use search to find older requests.
Freedom of Information Request Reference: 11703
Date Received: 09/07/2026
Summary:
How much of the annual unitary charge paid to PFI provider Consort for the Royal Infirmary of Edinburgh (RIE) to date has been set aside for use for lifecycle works by December 2027? And of that figure, how much has been spent on lifecycle works?
Date of Response: 07/08/2026
View Response: 11703.pdf
Freedom of Information Request Reference: 11702
Date Received: 09/07/2026
Summary:
A copy of all recorded communications between NHSL and the Scottish Government between January 1, 2025 and the date of this request which relate to the Commercial Compromise Joint Lifecycle Management and Supplemental Agreement (SA) agreed with Consort in relation to the end of the PFI deal at the Royal Infirmary of Edinburgh (RIE).
Date of Response: 07/08/2026
View Response: 11702.pdf
Freedom of Information Request Reference: 11701
Date Received: 09/07/2026
Summary:
Please provide full details of the legal costs incurred by NHSL in relation to agreeing the Commercial Compromise Joint Lifecycle Management and Supplemental Agreement (SA) with Consort in relation to the end of the PFI deal at the Royal Infirmary of Edinburgh (RIE).
Date of Response: 07/08/2026
View Response: 11701.pdf
Freedom of Information Request Reference: 11700
Date Received: 09/07/2026
Summary:
Please provide details of all lifecycle and remedial works which NHSL has identified as needed at the Royal Infirmary of Edinburgh (RIE) before it is returned to NHSL in 2027. To clarify, this part of my request is just for a description of all lifecycle and remedial works required, such as the fire stopping issue. Secondly, what is estimated cost of these lifecycle and remedial works.
Date of Response: 07/08/2026
View Response: 11700.pdf
Freedom of Information Request Reference: 11699
Date Received: 09/07/2026
Summary:
Please can I have a copy of the Commercial Compromise Joint Lifecycle Management and Supplemental Agreement (SA) agreed with Consort in relation to the end of the PFI deal at the Royal Infirmary of Edinburgh (RIE).
Date of Response: 07/08/2026
View Response: 11699.pdf
Freedom of Information Request Reference: 11671
Date Received: 03/07/2026
Summary:
1) What percentage of your Consultant Job Plans are still on 9:1 DCC:SPA contracts 2) How many Consultant jobs have been advertised as 9:1 DCC:SPA since the publication of DL (2025) 21 on 16th September 2025 requiring the cessation of this as a practice.
Date of Response: 31/07/2026
View Response: 11671.pdf
Freedom of Information Request Reference: 11670
Date Received: 03/07/2026
Summary:
How many early-stage (non-metastatic or Stages 1-3) non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with: •Atezolizumab (Tecentriq) •Durvalumab (Imfinzi) •Nivolumab (Opdivo) •Pembrolizumab (Keytruda) •Chemotherapy •Radiotherapy •Chemotherapy AND Radiotherapy •Osimertinib
Date of Response: 31/07/2026
View Response: 11670.pdf
Freedom of Information Request Reference: 11667
Date Received: 03/07/2026
Summary:
1. The number of patients under the trust’s care with a recorded diagnosis of Dravet syndrome from January-June 2026. Likely coded as ICD-10 code G40.3 or SNOMED code 230437002. a) Patient numbers segmented by age: i. <2 years old ii. 2-8 years old iii. 9-17 years old iv. 18 years+ 2. The number of patients under the trust’s care with a recorded diagnosis of Lennox-Gastaut syndrome from January-June 2026. Likely coded as ICD-10 code G40.4 or SNOMED code of 230418006. a) Patient numbers segmented by age: i. <2 years old ii. 2-8 years old iii. 9-17 years old iv. 18 years+ 3. The number of patients under the trust’s care who have been treated with fenfluramine from January-June 2026 a) Patient numbers segmented by age: i. <2 years old ii. 2-8 years old iii. 9-17 years old iv. 18 years+ b) For these patients, how many of them had a diagnosis of Dravet Syndrome (ICD10 Code: G40.3) SCTID: 230437002. Patient numbers segmented by age: i. <2 years old ii. 2-8 years old iii. 9-17 years old iv. 18 years+ c) For these patients, how many of them had a diagnosis of Lennox-Gastaut syndrome (ICD10 Code: G40.4) SCTID: 230418006. Patient numbers segmented by age: i. <2 years old ii. 2-8 years old iii. 9-17 years old iv. 18 years+ 4. The number of patients under the trust’s care who have been treated with cannabidiol from January-June 2026 a) Patient numbers segmented by age: i. <2 years old ii. 2-8 years old iii. 9-17 years old iv. 18 years+ b) For these patients, how many of them had a diagnosis of Dravet Syndrome (ICD10 Code: G40.3) SCTID: 230437002. Patient numbers segmented by age: i. <2 years old ii. 2-8 years old iii. 9-17 years old iv. 18 years+ c) For these patients, how many of them had a diagnosis of Lennox-Gastaut syndrome (ICD10 Code: G40.4) SCTID: 230418006. Patient numbers segmented by age: i. <2 years old ii. 2-8 years old iii. 9-17 years old iv. 18 years+ 5. The number of patients under the trust’s care who have been treated with cenobamate from January-June 2026 a) Patient numbers segmented by age: i. <2 years old ii. 2-8 years old iii. 9-17 years old iv. 18 years+ b) For these patients, how many of them had a diagnosis of Dravet Syndrome (ICD10 Code: G40.3) SCTID: 230437002. Patient numbers segmented by age: i. <2 years old ii. 2-8 years old iii. 9-17 years old iv. 18 years+ c) For these patients, how many of them had a diagnosis of Lennox-Gastaut syndrome (ICD10 Code: G40.4) SCTID: 230418006. Patient numbers segmented by age: i. <2 years old ii. 2-8 years old iii. 9-17 years old iv. 18 years+ 6. The number of patients under the trust’s care who have been treated with rufinamide from January-June 2026 a) Patient numbers segmented by age: i. <2 years old ii. 2-8 years old iii. 9-17 years old iv. 18 years+ b) For these patients, how many of them had a diagnosis of Lennox-Gastaut syndrome (ICD10 Code: G40.4) SCTID: 230418006. Patient numbers segmented by age: i. <2 years old ii. 2-8 years old iii. 9-17 years old iv. 18 years+ 7. The number of patients under the trust’s care who have been treated with stiripentol from January-June 2026 a) Patient numbers segmented by age: i. <2 years old ii. 2-8 years old iii. 9-17 years old iv. 18 years+ b) For these patients, how many of them had a diagnosis of Dravet Syndrome (ICD10 Code: G40.3) SCTID: 230437002. Patient numbers segmented by age: i. <2 years old ii. 2-8 years old iii. 9-17 years old iv. 18 years+
Date of Response: 31/07/2026
View Response: 11667.pdf
Freedom of Information Request Reference: 11662
Date Received: 02/07/2026
Summary:
(1) A complete breakdown of the backlog of repairs the St John’s Hospital (Livingston) requires including essential safety critical ones. Please make it clear what each repair is and by category which repairs are considered essential. Please also make it clear how many repairs in total are outstanding. (2) The current total cost of outstanding backlog of repairs. (3) A breakdown of each repair that has been made in the last six months and the total money that was spent on them.
Date of Response: 31/07/2026
View Response: 11662.pdf
Freedom of Information Request Reference: 11638
Date Received: 30/06/2026
Summary:
Please can you provide the estimated cost of the proposed project to redesign and relocate the Little France zebra crossing at the RIE. In addition, please can I have all minutes of the Short Life Working Group created to consider this change and other traffic management changes.
Date of Response: 31/07/2026
View Response: 11638.pdf
Freedom of Information Request Reference: 11503
Date Received: 18/05/2026
Summary:
1. How many new patients have been diagnosed with wild type Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in your Trust in the last 4 months? 2. How many new patients have been diagnosed with hereditary Transthyretin Amyloid Polyneuropathy (ATTR-PN) in your Trust in the last 4 months? 3. What is the total number of patients with wild type Transthyretin Amyloid Cardiomyopathy (ATTR-CM) being treated in your Trust? 4. What is the total number of patients with hereditary Transthyretin Amyloid Polyneuropathy (ATTR-PN) being treated in your Trust? 5. Of the newly diagnosed wild type ATTR-CM patients, how many were initiated with the following treatments a. Vutrisiran b. Tafamidis 61mg c. Acoramidis d. Enrolled in a clinical study 6. Of the newly diagnosed ATTR-PN patients, how many were initiated with the following treatments a. Vutrisiran b. Eplontersen c. Enrolled in a clinical study 7. What is your Trust’s protocol for confirming diagnosis of ATTR patients? Is diagnosis confirmed by your Trust or the National Amyloidosis Centre (NAC)? 8. Of the diagnosed patients, how many had their diagnosis made/confirmed a. In your Trust b. By the National Amyloidosis Centre (NAC) London or Midlands 9. How many patients have been confirmed for treatment initiation either a. Virtually b. In person
Date of Response: 31/07/2026
View Response: 11503.pdf
Freedom of Information Request Reference: 11396
Date Received: 15/04/2026
Summary:
Please can you tell me how many Intrahepatic Cholestasis of Pregnancy cases were recorded in your health board for each of the last ten years. In addition, please can you tell me how many stillbirths were recorded where Intrahepatic Cholestasis of Pregnancy was the cause of the stillbirth, again for each of the last ten years.
Date of Response: 31/07/2026
View Response: 11396.pdf
Freedom of Information Request Reference: 11268
Date Received: 09/03/2026
Summary:
Please provide me with the following information and documentation in relation to Craigmillar Medical Group, West End Medical Practice and Hopetoun Practice relating to the period beginning 1 January 2023 onwards: 1. all contractual documentation between NHS Lothian Health Board and the GP practices, in particular by way of implementation of the GMS contract; 2. details of the dispute resolution mechanism for contracts with the GP practices; 3. details of any enhanced services provided by the GP practices under the GMS contract; and 4. details of how the delivery of essential services by the GP practices under the GMS contract is monitored.
Date of Response: 31/07/2026
View Response: 11268.pdf
Freedom of Information Request Reference: 11680
Date Received: 07/07/2026
Summary:
Request in relation to medical records.
Date of Response: 08/07/2026
View Response: 11680.pdf
Freedom of Information Request Reference: 11666
Date Received: 02/07/2026
Summary:
The number of patients being removed from an NHS inpatient and day case treatment waiting list due to attending or being admitted to the private sector. I would like this information for the last 6 calendar years (2021, 2022, 2023, 2024, 2025 and 2026).
Date of Response: 30/07/2026
View Response: 11666.pdf
Freedom of Information Request Reference: 11664
Date Received: 02/07/2026
Summary:
Q1. In the last 6 months, how many patients have been diagnosed with Diffuse Large B Cell Lymphoma (DLBCL)? Q1a. Of these patients, how many commenced treatment at your trust within the last 6 months? Q2. In the last 6 months, how many patients have you treated for Diffuse Large B Cell Lymphoma (DLBCL) with the following treatments: •R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone) •R-mini-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone) •Pola-BR (polatuzumab vedotin with rituximab and bendamustine) •Pola-R-CHP (Polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin hydrochloride, and prednisolone) •R-CODOX-M (rituximab, cyclophosphamide, vincristine, doxorubicin and methotrexate) •R-IVAC (rituximab, ifosfamide, etoposide and cytarabine) •R-GCVP (Rituximab, gemcitabine, cyclophosphamide, vincristine, prednisolone) •(DA)-EPOCH +/-R (Prednisolone, doxorubicin, vincristine, etoposide, cyclophosphamide, rituximab) •R-GemOX (rituximab, gemcitabine and oxaliplatin) •Axicabtagene ciloleucel •Tisagenlecleucel •Epcoritamab •Loncastuximab tesirine •Glofitamab •Any other SACT •Stem cell transplant or bone marrow transplant (autologous or allogeneic) •Glofitamab + GemOx (gemcitabine and oxaliplatin) Q3. In the last 6 months, how many patients have received the following 2nd line treatments for Diffuse Large B Cell Lymphoma (DLBCL): •Axicabtagene ciloleucel (Yescarta) •Tisagenlecleucel •Pola-BR (polatuzumab vedotin with rituximab and bendamustine) •R-GemOX (rituximab, gemcitabine and oxaliplatin) •Stem cell transplant or bone marrow transplant (autologous or allogeneic) •Glofitamab + GemOx (gemcitabine and oxaliplatin) •Any other treatments Q4. In the last 6 months, how many patients has the Trust treated for 3rd line Diffuse Large B Cell Lymphoma (BLBCL)? Q5. In the last 6 months, how many patients have you referred to other trusts for the treatment of Diffuse Large B Cell Lymphoma (DLBCL) for the following treatments: •CAR-T Therapy (E.g. Axicabtagene ciloleucel) •Stem cell transplant or bone marrow transplant (autologous or allogeneic) •Any other treatment
Date of Response: 30/07/2026
View Response: 11664.pdf
Freedom of Information Request Reference: 11651
Date Received: 01/07/2026
Summary:
Would please let me have: 1. Your definition of an active case of influenza. 2. The methods used to confirm an influenza case and distinguish it from other viral acute respiratory infections.
Date of Response: 30/07/2026
View Response: 11651.pdf
Freedom of Information Request Reference: 11646
Date Received: 25/06/2026
Summary:
Please provide the following two figures for each of the four assessment types listed below, as current point-in-time figures where possible, or alternatively for the most recent available period: a) The median waiting time in weeks from GP referral to first assessment appointment b) The total number of people currently on the waiting list The four assessment types are: 1. Adult ADHD assessment 2. CAMHS (under 18) ADHD assessment 3. Adult autism assessment 4. CAMHS (under 18) autism assessment
Date of Response: 30/07/2026
View Response: 11646.pdf
Freedom of Information Request Reference: 11623
Date Received: 24/06/2026
Summary:
Please treat the following questions as part of an FOI request to NHS Lothian: 1) How many patients under the care of NHS Lothian are waiting for access to hybrid closed loop systems, for the management of diabetes 2) What is the average wait-time for access to a hybrid closed loop system once placed on the waiting list, in months. 3) How much did NHS Lothian spend on access to hybrid closed loop systems in the following financial years: 2023/24 2024/25 2025/26 2026/27 4) How much Scottish Government ring-fenced funding for hybrid closed-loop system access did NHS Lothian receive in the following financial years? 23/24 24/25 25/26 26/27
Date of Response: 30/07/2026
View Response: 11623.pdf
Freedom of Information Request Reference: 11622
Date Received: 25/06/2026
Summary:
Please provide the following data for each of the last three calendar years (2023, 2024, and 2025). Please categorise all data using the NHS standard 18+1 ethnic category codes. If granular data triggers privacy thresholds or Section 40 exemptions, please group them into broad categories (White, Black African, Black Caribbean, Mixed Black, Asian, Mixed/Other, and Not Stated/Unknown). Specifically, I request: 1. Total Diagnoses & Age Baseline The total number of patients newly diagnosed with prostate cancer (ICD-10 code C61), broken down by ethnic group. The median age at diagnosis for prostate cancer patients, broken down by ethnic group. The total number of individuals diagnosed under the age of 55, broken down by ethnic group. 2. Stage at Diagnosis The number and percentage of these patients diagnosed at Stage 1, Stage 2, Stage 3, and Stage 4, broken down by ethnic group. 3. Referral Route The primary route of referral (e.g., Urgent GP 2-Week Wait, routine GP referral, Emergency Admission, or Secondary Care transfer), broken down by ethnic group. 4. The Diagnostic Timeline The median number of days from the initial urgent GP referral to the diagnostic multiparametric MRI (mpMRI) scan, broken down by ethnic group. The median number of days from the mpMRI scan to a definitive prostate biopsy, broken down by ethnic group. 5. Root Cause of Target Breaches The percentage of patients who breached the national 62-day urgent referral-to-treatment target, broken down by ethnic group. For those patients who breached the 62-day target, provdea percentage breakdown of the primary Delay Reason Code (per the NHS National Cancer Waiting Times Monitoring Dataset), aggregated by ethnic group—especifically contrasting provider-driven delays (e.g., Capacity inadequate, Complex diagnostic pathway) against patient-driven delays (e.g., Patient Choice, Patient DNA). 6. Population Catchment Area Baseline The estimated total population size, or the percentage demographic breakdown, of the primary Integrated Care Board (ICB) or catchment area that this Trust serves.
Date of Response: 30/07/2026
View Response: 11622.pdf
Freedom of Information Request Reference: 11619
Date Received: 24/06/2026
Summary:
I am writing to request all information it holds detailing how many midwifery shifts were left unfilled across its maternity and neonatal services after being put out for agency or bank cover by the health board over the course of 2023/24, 2024/25, and 2025/26. The disclosure should include, but not be limited to, a breakdown of the number of the midwifery shifts that went unfilled at individual hospitals in the health board’s remit.
Date of Response: 30/07/2026
View Response: 11619.pdf
Freedom of Information Request Reference: 11567
Date Received: 08/06/2026
Summary:
This request seeks recorded information held by NHS Lothian concerning the administrative handling and statutory timeline breach of my previous information request, reference 11467. On June 8, 2026, I received an email from your office noting that the response was late "partly due to an unforeseen absence". Because this phrasing indicates that an individual absence was only a partial cause of the statutory breach, I am requesting the specific recorded information that identifies the other contributing factors, operational backlogs, or administrative dependencies involved in delaying this case. To satisfy this request, please provide copies of the following recorded information held by the Board: 1. Any internal communications, emails, or case notes circulated within the FOI team or between the FOI team and external departments regarding the tracking, allocation, and delay of request reference 11467 between May 6, 2026, and June 8, 2026. 2. The internal tracking logs, system audit history, or timeline metrics showing when the draft response for reference 11467 was completed by the case handler, when it was sent to senior management for authorization, and the date it was received by the Executive Director of Nursing for final sign-off. 3. Any recorded communications or memos detailing internal processing bottlenecks or clearance delays relevant to the sign-off period for this request during the first week of June 2026.
Date of Response: 02/07/2026
View Response: 11567.pdf
Freedom of Information Request Reference: 11546
Date Received: 02/06/2026
Summary:
The information requested relates to service organisation, referral pathways, multidisciplinary working and genetic testing pathways for women with known or suspected monogenic diabetes during pregnancy.
Date of Response: 30/07/2026
View Response: 11546.pdf
Freedom of Information Request Reference: 11490
Date Received: 12/05/2026
Summary:
We would be obliged if you could provide us with information in relation to any guidelines in place in July 2016 relating to neonatal cord gases, hypoxic ischemic encephalopathy and/or the requirement for resuscitation at the time of birth. In particular, we would be obliged for a copy of any guidelines that were in place at the time showing what normal blood gas ranges would be, what monitoring ought to be undertaken if blood gases were abnormal, and when a patient should be referred to the neonatal unit/special care baby unit. We would be obliged if this could cover both St John’s Hospital and Royal Infirmary of Edinburgh if there were different guidelines in place for the two hospitals at that time.
Date of Response: 30/07/2026
View Response: 11490.pdf
Freedom of Information Request Reference: 11432
Date Received: 27/04/2026
Summary:
What information resources (e.g. leaflets, websites, videos) are provided to patients about preimplantation genetic testing (PGT)? Are PGT information resources available in accessible formats (e.g. easy read, translated materials)? What resources do you have for providing emotional or psychological support to couples during the PGT process? What support is offered to patients or couples navigating PGT decision making and/or following PGT outcomes? Are patients signposted to any external organisations or charities relating to PGT, if so who and what resources are these? Are there any internal guidelines or standard operating procedures (SOPs) for staff on how to discuss PGT with patients? What educational resources or training do you have to support staff on discussing PGT with patients? Where possible, please provide copies or links to the resources referenced. The resources can be generic or disease specific.
Date of Response: 28/05/2026
View Response: 11432.pdf
Freedom of Information Request Reference: 11658
Date Received: 01/07/2026
Summary:
In every year since 2020/21, amongst women giving birth in maternity units in your health board, how many cases have there been of: 1. Minor primary postpartum haemorrhage; 2. Major primary postpartum haemorrhage; 3. Secondary postpartum haemorrhage and 4. Serious perineal tears? For (1), (2) (3) and (4), please can you also tell me what portion of all births in each year since 2020/21 these cases represented.
Date of Response: 29/07/2026
View Response: 11658.pdf
Freedom of Information Request Reference: 11657
Date Received: 01/07/2026
Summary:
I'm seeking a usage report for equipment drapes and incise drapes consumables used in operating theatres across all hospitals/sites in your trust for the last completed financial year (1 April 2025 – 31 March 2026). If readily available, please also include the current financial year to date (from 1 April 2026). -Trust site / hospital -Product code -Description -Manufacturer name and brand (if held) -Supplier (e.g., NHS Supply Chain or direct supplier) -Pack size & unit of measure -Quantity usage -Total spend for each product
Date of Response: 29/07/2026
View Response: 11657.pdf
Freedom of Information Request Reference: 11656
Date Received: 01/07/2026
Summary:
Q1. Please provide the total number of patients treated in the last 6 months for: •Polycythaemia Vera (ICD10 code D45) •Myelofibrosis (ICD10 code D47.4) •Myelofibrosis (ICD10 code D47.4) patients aged 65 and older Q2. How many patients were treated in the past 6 months (for any disease) with: •Ruxolitinib •Fedratinib •Momelotinib Q3. How many patients were treated with Ruxolitinib in the past 6 months for the following diseases? •Myelofibrosis (ICD10 code D47.4) •Polycythaemia Vera (ICD10 code D45) •Other/Unknown
Date of Response: 29/07/2026
View Response: 11656.pdf
Freedom of Information Request Reference: 11654
Date Received: 01/07/2026
Summary:
1. How many incidences of whistleblowing has NHS Lothian recorded in each of the last five financial years (please break down by year, 2021/22, 2022/23, 2023/24, 2024/25, 2025/26)? 2. Does your whistleblowing policy encourage or direct whistleblowers to raise concerns with a "prescribed person" (as defined under the Public Interest Disclosure Act 1998)? If so, please specify which prescribed person(s) are referenced. 3. Does your whistleblowing policy or process guarantee anonymity to individuals who raise a concern? If so, please provide a copy of the relevant section of the policy addressing this. 4. Does your whistleblowing policy include a non-recrimination or non-retaliation provision, protecting whistleblowers from detriment or reprisal as a result of raising a concern? If so, please provide a copy of the relevant section of the policy addressing this. 5. Has your internal whistleblowing policy been subject to any external review, audit, or assessment (by an external body, auditor, regulator, or independent consultant) within the last five years? If so, please provide: a. the name of the body/organisation that conducted the review; b. the date of the review; and c. a copy of any resulting report or summary of findings, subject to any applicable exemptions.
Date of Response: 29/07/2026
View Response: 11654.pdf
Freedom of Information Request Reference: 11650
Date Received: 01/07/2026
Summary:
In the period 1st April 2026 to 30th June 2026 please provide a breakdown of: • Total trust spend with framework agencies for locum nurses Please provide a further breakdown for locum nurses by: • Spend per band • Spend per specialty • Spend per agency name In the period 1st April 2026 to 30th June 2026 please provide a breakdown of: • Total trust spend with off framework agencies for locum nurses Please provide a further breakdown for locum nurses by: • Spend per band • Spend per specialty • Spend per agency name In the period 1st April 2026 to 30th June 2026 please provide a breakdown of: • Total trust spend with the internal trust bank or associated external provider for locum nurses Please provide a further breakdown for locum nurses by: • Spend per band • Spend per specialty • Spend per agency name Please confirm the total number of nursing shifts booked during this period for all agency nursing only, no bank staff nursing to be included (1st April 2026 to 30th June) Please confirm the total number of nursing shifts booked above NHSE capped rates during this period for all agency nursing only, no bank staff nursing to be included (1st April 2026 to 30th June 2026) Please confirm the framework you utilise for nursing agency staff.
Date of Response: 29/07/2026
View Response: 11650.pdf
Freedom of Information Request Reference: 11649
Date Received: 30/06/2026
Summary:
For the time period 1st April 2025 to 31st March 2026 (or your nearest 12-month period), please provide the following: 1. total number of violent incidents on your staff broken down by job title/category of worker 2. a breakdown of the nature of the violent incident e.g. verbal, physical, threatening behaviour 3. how many violent incidents have been reported under RIDDOR (Reporting of Injuries, Diseases and Dangerous Occurrences) Regulations, with a breakdown by job title/category of worker Please could you break this information down into incidents involving female staff / male staff.
Date of Response: 28/07/2026
View Response: 11649.pdf
Freedom of Information Request Reference: 11648
Date Received: 01/07/2026
Summary:
I am seeking information relating to procedures recorded under OPCS-4 code H44.1. Please provide, for each financial year (or calendar year if more readily available) from 2016 to 2026, the following: 1. The number of H44.1 procedures performed. 2. The total number of bed days associated with patients undergoing H44.1 procedures. 3. The total clinical cost associated with these procedures, where recorded and available. If possible, please provide the above data: *Broken down by sex. *Broken down by age group (for example: under 20, 20–29, 30–39, 40–49, 50–59, 60–69, 70–79, 80+).
Date of Response: 29/07/2026
View Response: 11648.pdf
Freedom of Information Request Reference: 11645
Date Received: 30/06/2026
Summary:
1 Does your Trust/Health Board currently have an orthotics service? 2 Does your Trust/Health Board provide bracing (chest brace and/or vacuum bell) for Pectus deformities? 3 If you answered Yes to Question 2: Does your service provide bracing for Pectus Carinatum, Pectus Excavatum, or both? 4 If you answered Yes to Question 2: Is the orthotics service responsible for the provision of the brace and/or vacuum bell? 5 If you answered No to Question 4: Which service is responsible for the provision of the brace and/or vacuum bell? 6 If you answered No to Question 2: Are there any plans for your Trust/Health Board to begin providing this service? 7 Over the last 3 years, have you seen an increase in the number of referrals for bracing of Pectus conditions?
Date of Response: 28/07/2026
View Response: 11645.pdf
Freedom of Information Request Reference: 11643
Date Received: 25/06/2026
Summary:
I am writing to request contact information for all General Practitioner (GP) practices currently operating within your health board's jurisdiction. Specifically, I request that the data be provided in an electronic format (CSV or Excel) containing the following fields for each practice: • Official NHS Practice Code • GP Practice / Surgery Name • Main Administrative or Public Contact Email Address (e.g. reception, enquiries, or practice manager)
Date of Response: 28/07/2026
View Response: 11643.pdf
Freedom of Information Request Reference: 11640
Date Received: 30/06/2026
Summary:
The NHS Lothian Specialist Practitioner District Nurses are required to hold the Specialist Practitioner Qualification (SPQ) which is 120 credits at SCQF Level 11 (Masters level) and are awarded 196 JE points/Level 7 at the Knowledge Training and Experience (KTE) factor by NHS Lothian Job Evaluation. The NHS Lothian Specialist School Nurses have been required (since earlier than 2018) to hold the Specialist Community Public Health Nurse Qualification (SCPHN) which is 120 credits at SCQF Level 11 (Masters level) and they are awarded only 156 JE points/Level 6 points at the Knowledge Training and Experience (KTE) factor by NHS Lothian Job Evaluation. Please explain why NHS Lothian Specialist School Nurses have been awarded 40 points less at KTE than Specialist Practitioner District Nurses who hold the exact same Masters Level of qualification. They both evidence the same level of Knowledge Training and Experience: 120 credits at Masters level/SCQF level 11. Why are the evaluations so unequal?
Date of Response: 28/07/2026
View Response: 11640.pdf
Freedom of Information Request Reference: 11637
Date Received: 29/06/2026
Summary:
Can I request, broken down by the calendar years 2019, 2020, 2021, 2022, 2023, 2024, 2025 and 2026 (most recent data): 1. How many midwifery shifts have gone unfilled after being put out for agency or bank cover, broken down by position. 2. How many obstetrics shifts have gone unfilled after being put out for locum cover, broken down by position (e.g. consultant, resident doctor).
Date of Response: 28/07/2026
View Response: 11637.pdf
Freedom of Information Request Reference: 11636
Date Received: 29/06/2026
Summary:
Q1. How many patients received treatment for any condition in the last six months with any of the following treatment regimens (November 2025 – April 2026)? •Ocrevus (ocrelizumab) IV (300mg/30ml) •Ocrevus (ocrelizumab) Subcutaneous (920mg/23ml) •Kesimpta (ofatumumab) •Briumvi (ublituximab) •Mavenclad (cladribine) •Dimethyl Fumarate (Tecfidera + Dimethyl Fumarate generic) •Natalizumab (Tysabri and Tyruko) Q1a. Of the patients identified in question one, how many patients received the same treatment in the previous six-month period? (i.e. How many of the same patients received treatment with each treatment regimen in May 2025 to October 2025 AND November 2025-April 2026) •Ocrevus (ocrelizumab) IV (300mg/30ml) •Ocrevus (ocrelizumab) Subcutaneous (920mg/23ml) •Kesimpta (ofatumumab) •Briumvi (ublituximab) •Mavenclad (cladribine) •Dimethyl Fumarate (Tecfidera + Dimethyl Fumarate generic) •Natalizumab (Tysabri and Tyruko) Q2. How many patients have received a new diagnosis for Multiple Sclerosis in the latest six-month period (November 2025 – April 2026)? Q2a. Of the patients identified in question two, how many of these patients have received any of the following treatment regimens as their first treatment following their Multiple Sclerosis diagnosis? •Ocrevus (ocrelizumab) IV (300mg/30ml) •Ocrevus (ocrelizumab) Subcutaneous (920mg/23ml) •Kesimpta (ofatumumab) •Briumvi (ublituximab) •Mavenclad (cladribine) •Dimethyl Fumarate (Tecfidera + Dimethyl Fumarate generic) •Natalizumab (Tysabri and Tyruko)
Date of Response: 28/07/2026
View Response: 11636.pdf
Freedom of Information Request Reference: 11635
Date Received: 29/06/2026
Summary:
Does NHS Lothian have any local guidelines/protocols for the treatment of Immune thrombocytopenia (ITP)?
Date of Response: 24/07/2026
View Response: 11635.pdf
Freedom of Information Request Reference: 11631
Date Received: 29/06/2026
Summary:
Do you routinely use robotic surgery to perform endometriosis surgery?
Date of Response: 27/07/2026
View Response: 11631.pdf
Freedom of Information Request Reference: 11630
Date Received: 26/06/2026
Summary:
Please can I request the following information: (1) Is venison currently served in meals for patients or staff at your hospital board? (2) If the answer to (1) is yes, how many hospitals is venison currently served in? (3) How much venison, in kilograms, was included in patient meals or staff meals in the last year? (4) What percentage of venison served in your hospital was sourced in Scotland?
Date of Response: 28/07/2026
View Response: 11630.pdf
Freedom of Information Request Reference: 11628
Date Received: 25/06/2026
Summary:
I am writing to request information under the Freedom of Information Act 2000. I would like to receive the following information: Total funding and budget available to NHS Lothian for the noted financial years: o 2022/2023 o 2023/2024 o 2024/2025 A breakdown of the funding allocated to each department, for example, cardiology, gynaecology, children’s mental health etc. I would ask for this department breakdown to be provided for the same financial years that are highlighted above. How much funding has been allocated to clinical trials as per each department and how many clinical trials were held for each department listed for each of the time periods outlined above.
Date of Response: 29/07/2026
View Response: 11628.pdf
Freedom of Information Request Reference: 11627
Date Received: 25/06/2026
Summary:
The information I’m asking for concerns each of the financial years: 2020/21, 2021/22, 2022/23, 2023/24, 2024/25, 2025/26. Could you provide me with internal and external reports, briefings, research documents, newsletters and surveys produced by the health board concerning the workforce only, in relation to diversity, equity and inclusion (DEI) and ethnic minority staff?
Date of Response: 28/07/2026
View Response: 11627.pdf
Freedom of Information Request Reference: 11626
Date Received: 25/06/2026
Summary:
The information I’m asking for concerns each of the financial years: 2020/21, 2021/22, 2022/23, 2023/24, 2024/25, 2025/26. For each question, please provide an annual figure and a total across all six years. 1a. The number of single employment tribunal (ET1) claims brought against the Health Board 1b. Of those, how many were discrimination claims for: Age Disability Gender reassignment Marriage and civil partnership Pregnancy and maternity Race Religion or belief Sex Sexual orientation 1c. The outcome of each claim 1d. The amount awarded for each claim 2a. The number of claims that went to Acas for early conciliation 2b. Of those, how many were discrimination claims for: Age Disability Gender reassignment Marriage and civil partnership Pregnancy and maternity Race Religion or belief Sex Sexual orientation 2c. The outcome of each claim 2d. The financial settlement reached for each claim 3. The number of workplace grievances for race discrimination or racism that were upheld
Date of Response: 28/07/2026
View Response: 11626.pdf
Freedom of Information Request Reference: 11625
Date Received: 25/06/2026
Summary:
Please provide the date when your medical device (as defined by MHRA, i.e. also including relevant software) procurement policy (or policies, if you e.g. have a separate one for medical software) was/were last updated. Please state whether the policy (mentioned in point 1 above) requires that a clinical ethicist should be consulted during purchase decisions (if a clinical ethicist is only needs to be consulted under certain conditions, please list these). A clinical ethicists is defined as a member of your clinical ethics committee (under whatever name it operates in your organisation, but this does not include research ethics committees) or an academic with a dedicated post in ethics or a permanent staff members explicitly employed to provide clinical ethics support. If the policy requires ethical issues to be considered during such devise purchase decisions, but not via input of a clinical ethicist as defined above, please state the mechanisms in place for fulfilling that requirement. Please state whether you had clinical ethicist (as defined above) involvement in the purchase of any clinical artificial intelligence applications irrespective of whether this is mandated by your policy.
Date of Response: 28/07/2026
View Response: 11625.pdf
Freedom of Information Request Reference: 11624
Date Received: 25/06/2026
Summary:
1. Please could you supply the name, email address and telephone number of the commissioner with responsibility for learning disabilities placements? For questions 2 to 4, please supply this information as a snapshot at the end of the year for the financial year 2025/26 and the most up to date snapshot available for 2026/27. 2. Please provide the total number of adults aged 18-64 with learning disabilities and/or autism funded by the TRUST in residential care. 3. Of the total number of adults aged 18-64 with learning disabilities and/or autism funded by the Trust in residential care (q.2), please provide the number that are in ‘in area’ placements and the number that are in ‘out of area’ placements. 4. Please provide the total number of adults aged 18-64 with learning disabilities and/or autism funded by the Trust in supported living. 5. Please provide the Trust’s total expenditure on residential care and supported living for adults aged 18-64 with learning disabilities and/or autism for the financial year 2025/26, and budgeted expenditure for 2026/27. 6. Please provide the highest, lowest, and average weekly rate paid by the Trust for residential care placements for adults aged 18-64 with learning disabilities and/or autism for each of the financial years 2025/26 and 2026/27. If the Trust has weekly rate bands, please also provide these. 7. Please provide the number of adults aged 18-64 with learning disabilities and/or autism funded by the Trust in residential care with fees per week of: • Less than £1,500 • £1,500 to £2,999 • £3,000 to £4,999 • £5,000 or more 8. Please provide a list of providers used by the Trust to deliver long-term residential care to adults aged 18-64 with learning disabilities and/or autism. For each named provider, please provide both of the following for the same single month — the most recent full calendar month available (or, if a single month cannot be provided, the financial year 2025/26): a. the number of such adults funded by the Trust in long-term residential placements with that provider in that month; and b. the Trust’s total gross expenditure with that provider for that month, including all payments for these placements (e.g. any block/core hours). Please use the same month for (a) and (b) and confirm which month, so the two figures are directly comparable. 9. Does the Trust consider there is sufficient local residential care provision to meet the needs of adults aged 18-64 with learning disabilities and/or autism who have a high level of complex needs, and which providers does the Trust mainly use for these placements? What are the occupancy levels locally?
Date of Response: 22/07/2026
View Response: 11624.pdf
Freedom of Information Request Reference: 11620
Date Received: 24/06/2026
Summary:
I am writing to request under the Freedom of Information (Scotland) Act 2002 that the health board disclose all information it holds detailing how many recorded instances there were of maternity and neonatal services being placed on ‘divert’ over the course of 2023/24, 2024/25, and 2025/26, meaning that they were temporarily closed to new admissions, with patients being redirected to alternative hospitals. The disclosure should include, but not be limited to, a year-by-year breakdown of how many patients were impacted, the hospitals where the patients were diverted from, where they were eventually treated, and a brief summary of why the services were placed on ‘divert’ on each occasion.
Date of Response: 23/07/2026
View Response: 11620.pdf
Freedom of Information Request Reference: 11618
Date Received: 24/06/2026
Summary:
I am writing to request under the Freedom of Information (Scotland) Act 2002 that the health board disclose all information it holds detailing how many serious adverse events were recorded across the health boards maternity and neonatal services between 2023/24, 2024/25, and 2025/26. The disclosure should include, but not be limited to, a breakdown of the number of serious adverse events that were recorded at individual hospitals across the health board’s area. The disclosure should also summarise the category and/or nature of the serious adverse incident, such as staff shortages, medicines administered in error, or treatment delays.
Date of Response: 20/07/2026
View Response: 11618.pdf
Freedom of Information Request Reference: 11617
Date Received: 24/06/2026
Summary:
I am writing to request under the Freedom of Information (Scotland) Act 2002 that the health board disclose all information it holds detailing how many complaints it has received regarding its maternity and neonatal services and the care provided by its maternity and neonatal services over the course of 2023/24, 2024/25, and 2025/26 The disclosure should include, but not be limited to, details of how many of the complaints were fully upheld, partially upheld. It should also include, but not be limited to, a brief summary of the nature of the complaint, examples of which may include the likes of misdiagnosis, out of date medication, and anaesthesia procedures.
Date of Response: 20/07/2026
View Response: 11617.pdf
Freedom of Information Request Reference: 11615
Date Received: 23/06/2026
Summary:
In 1905 the grounds at Belhaven Community Hospital were given by George Warrender, 7th Bart of Lochend to the "County Council of the County of Haddington and the Provost, Magistrates and Councillors of the burgh of Dunbar". There were several conditions in this bequest. It is now to be disposed of by NHS Lothian. In between these times the land has obviously been transferred in ownership and there are presumably the current deeds and similar documents showing ownership by NHSL. I wish to make a request under the Freedom of Information Act Scotland to see the record of the land ownership documentation showing the changes between then and now, especially any where the original conditions were changed.
Date of Response: 20/07/2026
View Response: 11615.pdf
Freedom of Information Request Reference: 11614
Date Received: 23/06/2026
Summary:
1. A copy of the organisation’s current policy or policies relating to sexual misconduct and/or sexual harassment 2. Copies of any records, reports, meeting minutes, policy review documents, or other documentation showing changes, updates, reviews, or amendments made to these policies since 26 October 2024, when the Worker Protection (Amendment of Equality Act 2010) Act 2023 came into effect. 3. Copies of any records showing how these policies have been communicated or promoted to staff since 26 October 2024, including (but not limited to) staff communications, training materials, intranet announcements, awareness campaigns, guidance documents, or briefing materials. 4. Details of the policies, procedures, reporting channels, and guidance available to staff for reporting sexual misconduct or harassment, including any mechanisms that allow reports to be made anonymously or confidentially.
Date of Response: 20/07/2026
View Response: 11614.pdf
Freedom of Information Request Reference: 11612
Date Received: 22/06/2026
Summary:
I would like to know how many patients in East Lothian have been prescribed Munjaro for weight loss since it has been approved by Lothian Health Board.
Date of Response: 10/07/2026
View Response: 11612.pdf
Freedom of Information Request Reference: 11611
Date Received: 22/06/2026
Summary:
1. How many male acute mental health admissions to the independent sector have you had in the last 12 months? 2. Please list the hospitals where these male acute mental health admissions have been placed in the last 12 months? 3. How many female acute mental health admissions to the independent sector have you had in the last 12 months? 4. Please list the hospitals where these female acute mental health admissions have been placed in the last 12 months? 5. How many male PICU admissions to the independent sector have you had in the last 12 months? 6. Please list the hospitals where these male PICU admissions have been placed in the last 12 months? 7. How many female PICU admissions to the independent sector have you had in the last 12 months? 8. Please list the hospitals where these female PICU admissions have been placed in the last 12 months?
Date of Response: 10/07/2026
View Response: 11611.pdf
Freedom of Information Request Reference: 11610
Date Received: 22/06/2026
Summary:
This request concerns NHS Lothian’s governance, oversight, and performance management arrangements for General Medical Services (GMS) and Primary Medical Services (PMS) contractors, including compliance with the NHS Scotland Model Complaints Handling Procedure (CHP). Please provide the following documents, policies, procedures, and governance frameworks currently used by NHS Lothian relating to GP contractor oversight: 1. GP Contractor Oversight Frameworks • GP contractor governance frameworks • Primary Care oversight policies • Documents describing NHS Lothian’s statutory duties under the National Health Service (Scotland) Act 1978 • Board level or Directorate level documents describing how NHS Lothian monitors compliance with GMS/PMS contracts • Internal guidance on escalation routes when concerns arise about a GP practice 2. Monitoring and Enforcement of CHP Compliance • Policies, procedures, or guidance describing how NHS Lothian monitors GP contractor compliance with the NHS Scotland Model Complaints Handling Procedure (CHP) • Any documents describing how NHS Lothian identifies GP practices that fail to follow the CHP • Any procedures for intervening when a GP practice: – fails to issue Stage 1 or Stage 2 acknowledgements – fails to issue Stage 2 outcomes – fails to meet statutory timescales – fails to provide updates or delay notices • Any escalation routes, sanctions, or enforcement mechanisms available to NHS Lothian when a GP contractor does not comply with the CHP • Any reports, audits, or reviews relating to GP practice compliance with the CHP 3. Performance Management and Quality Assurance • Policies on GP performance monitoring • Procedures for identifying underperformance • Documents describing how NHS Lothian: – assesses quality – monitors risk – reviews clinical governance – evaluates compliance with the GMS contract • Templates or frameworks used for practice reviews, audits, or inspections 4. Complaints, Escalation, and Intervention • Policies describing NHS Lothian’s role in GP complaints • Procedures for escalating concerns about GP practices • Documents describing: – when NHS Lothian intervenes in a GP practice – how concerns are triaged – how governance failures are recorded – how issues are escalated to the Scottish Government or the Primary Care Directorate 5. Equality Act 2010 Compliance in GP Practices • Policies describing NHS Lothian’s oversight of Equality Act compliance in GP practices • Documents describing how NHS Lothian ensures GP contractors meet their duties under: – the Equality Act 2010 – the Public Sector Equality Duty (PSED) • Any guidance issued to GP practices on communication reasonable adjustments 6. Data Protection, Record Keeping, and Governance • Policies describing NHS Lothian’s oversight of GP data protection compliance • Documents describing how NHS Lothian monitors: – accuracy of GP records – SAR handling – data minimisation – information governance failures • Escalation procedures when a GP practice fails to meet UK GDPR obligations 7. Communications Between NHS Lothian and GP Practices • Policies governing communication between NHS Lothian and GP contractors • Documents describing: – how NHS Lothian issues instructions to GP practices – how governance concerns are communicated – how practices are required to respond – how NHS Lothian records and tracks these communications 8. Board Level Oversight • Minutes, reports, or papers submitted to NHS Lothian Board or committees relating to GP contractor oversight • Documents describing the Board’s responsibilities for: – monitoring GP performance – ensuring contract compliance – addressing systemic issues in primary care
Date of Response: 20/07/2026
View Response: 11610.pdf
Freedom of Information Request Reference: 11609
Date Received: 22/06/2026
Summary:
1. Single-shot chest wall blocks in the Emergency Department a. Does your Trust provide single-shot ultrasound-guided chest wall blocks (e.g. serratus anterior plane block [SAPB] or erector spinae plane block [ESPB]) for adults with traumatic rib fractures in the Emergency Department prior to hospital admission? If yes: b. Which specialty or specialties perform these blocks (e.g. Emergency Medicine, Anaesthetics, Critical Care)? c. Are these blocks delivered as part of a formal pathway or standard clinical practice? d. Following a single-shot block, is it standard practice for patients to be considered for escalation to a continuous chest wall catheter (e.g. SAPB or ESPB catheter) and/or epidural analgesia? If not: e. If single-shot chest wall blocks are not routinely performed in the Emergency Department, are they routinely performed later during the patient's admission for traumatic rib fractures? f. Which specialty or specialties perform these blocks ? 2. Continuous chest wall catheter techniques a. Does your Trust provide continuous chest wall catheter techniques (e.g. SAPB or ESPB catheters) for adults admitted with traumatic rib fractures? If yes: b. Which specialty or specialties perform these procedures? c. In which clinical areas are these procedures typically performed (e.g. Emergency Department, Anaesthetic Room, Operating Theatre, Critical Care Unit, Ward)? d. Are patient selection criteria used (e.g. STUMBL Score, Battle Score, RibScore, or other risk stratification tools)? If so, please specify. 3. Policy and guidance a. Please attach a copy of all the specific guidelines and/or protocol and/or standard operational procedure for the chest wall blocks (including any competence/training/education if one is in place) If no specific local guideline or SOP exists for this, please explicitly state 'No local guideline held' 4. Physiotherapy management of rib fractures a. Does your Trust provide specific physiotherapy interventions for adults with traumatic rib fractures, including patients discharged directly from the Emergency Department? Examples may include incentive spirometry, breathing exercises, respiratory physiotherapy, kinesiology taping (K-tape), or other structured interventions. If yes: b. Please describe the interventions provided. c. Please provide copies of any associated guidelines, pathways, SOPs, patient information leaflets, or physiotherapy protocols. If no such documents are held, please state:"No local guideline held." 5. Other rib fracture management pathways a. Please provide copies of any additional local guidelines, pathways, SOPs, protocols, or care bundles relating to the management of adults with traumatic rib fractures that have not already been provided in response to Questions 3 and 4. This includes the Emergency Department, inpatient, surgical, medical, trauma, critical care, and physiotherapy pathways. If no additional documents are held, please state: "No other local guideline held." 6. Patient disposition a. For adults with multiple traumatic rib fractures who do not require Level 2 or Level 3 care, to which ward or specialty area are they most commonly admitted? 7. Specialty a. ‎ In your Trust, which parent speciality or specialities (e.g. Emergency Medicine, Frailty, Respiratory, Trauma & Orthopaedics, Cardiothoracic, or General Surgery) mainly look after adults with multiple rib fractures from blunt chest wall trauma as an inpatient for the first 5-7 days?
Date of Response: 20/07/2026
View Response: 11609.pdf
Freedom of Information Request Reference: 11608
Date Received: 16/06/2026
Summary:
I am writing to make a request for information under the Freedom of Information Act 2000, relating to the governance and management of Patient Group Directions (PGDs) within your Integrated Care Board and across your system. We recognise that PGD governance within an ICB may be fully or partially devolved to member organisations, GP federations, primary care networks, or community providers. The primary purpose of this request is to understand how PGD governance is structured across your system, and to identify the most appropriate contacts at each level. 1. Does your ICB hold central oversight or coordination of PGD governance across your system? Please indicate: Yes — managed centrally / Partial — oversight held centrally but operational management devolved / No — fully devolved to member organisations / Unknown 2. If PGD governance is fully or partially devolved, please identify which organisations within your system are responsible, where known. For example: GP federations, Primary Care Networks, acute trusts, community trusts, NHS 111/urgent treatment centres, community pharmacy contractors. Please name these organisations where possible. 3. Does your ICB have any system-wide PGD policy, framework, template, or register that applies across member organisations? If yes, please briefly describe its scope and format. 4. Who is the most appropriate contact within your ICB for medicines governance or PGD matters? Please provide name, job title, and email address. 5. Where PGD governance is devolved, please provide the name, job title, and email address of the most appropriate contact at each member organisation, or indicate who would be best placed to redirect this request. 6. If this request is being redirected or forwarded to another organisation, please confirm the name and contact details of that organisation.
Date of Response: 10/07/2026
View Response: 11608.pdf
Freedom of Information Request Reference: 11607
Date Received: 19/06/2026
Summary:
I request the following information regarding overseas travel undertaken by Board staff in connection with the sourcing or assessment of medical equipment or supplies from manufacturers or suppliers based outwith the UK and EU, for the period 1 April 2020 to date. 1. A list of all overseas trips undertaken by Board employees for the purpose of supplier visits, factory or warehouse inspections, supplier audits, or equivalent procurement-related activity, including destination, dates, and the supplier or manufacturer visited. 2. For each trip, please state who funded the travel and accommodation (i.e. the Board, the supplier/manufacturer, a third party, or a combination), and the total cost to the Board if any. 3. For each trip, please confirm the class of travel booked and the type of accommodation booked. 4. Please confirm whether any contracts, framework agreements, or purchase orders were subsequently awarded to a supplier or manufacturer visited as part of such a trip, including the value and date of any resulting contract. 5. Copies of any hospitality, gifts, or conflicts of interest register entries relating to procurement staff involved in sourcing medical equipment from overseas suppliers during this period. 6. Copies of flight booking confirmations, e-tickets, or travel expense claims relating to any of the trips described above. 7. Please search the mailbox of the Head of Procurement (or equivalent senior procurement role) for the search terms "warehouse visit", "factory visit", "site visit", and "supplier visit" for the period 1 April 2020 to date, and provide any resulting correspondence relating to arranging or approving overseas supplier travel.
Date of Response: 10/07/2026
View Response: 11607.pdf
Freedom of Information Request Reference: 11606
Date Received: 19/06/2026
Summary:
I would like to request information about: 1) provider name, 2) contract start and end dates including any extensions and 3) annual contract spend for the third-party software and service providers currently contracted by your Trust for these workforce management functions: 1. bank service for allied health professionals 2. bank service for nurses 3. bank service for medics 4. job planning for allied health professionals
Date of Response: 10/07/2026
View Response: 11606.pdf
Freedom of Information Request Reference: 11605
Date Received: 17/06/2026
Summary:
The number of immunoglobulin vials/volume in grams distributed to NHS Lothian in each month for January, February, and March 2026, broken down by product (see below). I would also like to request the number of patients by brand if available * Vigam * Flebogamma DIF * Gammaplex * Gamunex-C * Octagam * Gamten * Kiovig * Intratect * Privigen * Iqymune * Gammanorm * Subcuvia * Subgam * Hizentra * Hyqvia * Cuvitru * Panzyga * Xembify * Cutaquig •Vyvgart (Efgartigimod)
Date of Response: 20/07/2026
View Response: 11605.pdf
Freedom of Information Request Reference: 11604
Date Received: 19/06/2026
Summary:
1. Does your Health Board currently provide NHS assessment for adults (aged 18 and over) with suspected ADHD? 2. Which service or department carries out these assessments? 3. Are referrals accepted from GPs? 4. What are the current eligibility criteria for referral? 5. What is the current average waiting time from referral to first assessment? 6. How many adults are currently awaiting assessment? 7. Does the Health Board accept diagnoses made by private ADHD specialists for the purposes of ongoing NHS care? 8. Does the Health Board operate a shared-care prescribing arrangement between specialists and GPs for ADHD medication? 9. If shared-care arrangements are available, are they available across the whole Health Board area or only in certain GP practices? 10. If adult ADHD assessments are not currently provided, are there plans to establish or commission such a service?
Date of Response: 20/07/2026
View Response: 11604.pdf
Freedom of Information Request Reference: 11603
Date Received: 18/06/2026
Summary:
1. What is the total size of the maintenance backlog, as of 1 April 2026 (or most recent). 2. Provide the total size of the maintenance backlog in pounds sterling (£) at the end of each financial year from 2019/20 to 2026/27.
Date of Response: 28/07/2026
View Response: 11603.pdf
Freedom of Information Request Reference: 11602
Date Received: 18/06/2026
Summary:
For each financial year from 2020/21 to the most recent year available: 1. The total number of complaints received relating to maternity services. 2. The number of maternity complaints identified through keyword searches of complaint records using any of the following terms (or similar variants used by the Board): • birth trauma • traumatic birth • post-traumatic stress disorder (PTSD) • mental trauma following childbirth • informed consent • failure to obtain consent • not listened to / concerns ignored • birth injury • perineal tear • obstetric anal sphincter injury (OASI)
Date of Response: 14/07/2026
View Response: 11602.pdf
Freedom of Information Request Reference: 11599
Date Received: 17/06/2026
Summary:
Q1. How many patients have been treated in the past 3 months with the following agents for melanoma (any stage) : •Cobimetinib •Dabrafenib •Dabrafenib + Trametinib •Dacarbazine •Denosumab •Encorafenib + Binimetinib •Ipilimumab monotherapy •Ipilimumab + Nivolumab •Nivolumab monotherapy •Nivolumab + Relatlimab •Pembrolizumab •Pembrolizumab injection (Subcutaneous) •Trametinib •Vemurafenib •Vemurafenib + Cobimetinib •Other active systemic anti-cancer therapy •Palliative care only Q2. If possible, could you please provide the patients treated in the past 3 months with the following agents for metastatic melanoma ONLY : •Ipilimumab monotherapy •Ipilimumab + Nivolumab •Nivolumab monotherapy •Nivolumab + Relatlimab •Pembrolizumab •Any Targeted Therapy (Dabrafenib /Dabrafenib AND Trametinib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib) •Other active systemic anti-cancer therapy •Palliative care only Q3. In the last 3 months, how many patients have been initiated* on the following agents for treatment for melanoma? : •Ipilimumab (monotherapy) •Nivolumab (monotherapy) •Nivolumab AND Ipilimumab (combination) •Nivolumab AND Relatlimab •Pembrolizumab •Any Targeted Therapy (Dabrafenib /Dabrafenib AND Trametinib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib) •Other active systemic anti-cancer therapy *Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen. Q4. Does your trust participate in any clinical trials for Melanoma? If so, please provide the name of each trial, and the number of patients taking part.
Date of Response: 10/07/2026
View Response: 11599.pdf
Freedom of Information Request Reference: 11598
Date Received: 17/06/2026
Summary:
Questionnaire in relation to diagnosis of Alzheimer's Disease.
Date of Response: 10/07/2026
View Response: 11598.pdf
Freedom of Information Request Reference: 11597
Date Received: 17/06/2026
Summary:
To clarify the impact of current pathway management and ensure the transparency of waiting list data, please provide the following for the financial year 2025/26: Part 1: Performance and Waiting List Data Waiting List Volume: What is the current total number of adult patients on the urology waiting list for therapeutic circumcision? Median Wait Time: What is the current median waiting time (in weeks) for adult patients from "Decision to Treat" to the procedure date? Procedure Breakdown: Please provide the total number of adult therapeutic circumcisions performed in the last 12 months, broken down by: Method: Manual Suture vs. Automated Stapler. Anaesthetic: General Anaesthetic (GA) vs. Local Anaesthetic (LA). Part 2: Clinical Governance and Procedural Classification 4. Definition of "Major Surgery": Please provide the Trust’s formal Clinical Governance or SOP document defining "Major Surgery." What clinical metrics are used to categorize a 15-minute procedure as "Major" rather than "Minor" or "Day-Case"? 5. Benchmarking: Does the Trust classify other elective procedures with similar operative times (e.g., vasectomies) as "Major Surgery"? If not, please provide the clinical risk assessment that necessitates a different classification for stapler-assisted circumcision. 6. Resource Utilization: Has the Trust performed a Cost-Benefit Analysis (CBA) or a Resource Utilization Review comparing the cost of performing this procedure in a Main Theatre suite versus a designated outpatient procedure room? Part 3: Innovation and Consent 7. Device Specifications: What is the manufacturer and model of the stapler device currently utilized? 8. Implementation Timeline: When was this technology first introduced/commissioned within the Board? 9. Patient Information: Please provide a copy of the Patient Information Leaflet currently provided to patients undergoing this procedure. If no leaflet exists, please explain how the Board satisfies the requirements of Montgomery v Lanarkshire (2015) to inform patients of "reasonable alternatives" (e.g., choice between manual suture vs. automated stapler). 10. Incident Reporting: Please confirm if any clinical incident reports or formal complaints have been logged in the last 24 months specifically concerning the choice of surgical technique, or the lack of outpatient availability for this procedure. Part 4: Waiting List Integrity and "Hidden" Backlogs 11. Pre-pathway Volumes: How many patients are currently being held in a "pre-pathway," "pending," or "waiting for booking" status who have received a "Decision to Treat" but have not yet had their Referral to Treatment (RTT) clock formally started? 12. DTT to RTT Delay: For the last 12 months, what is the average duration (in days) between a patient’s "Decision to Treat" and the formal RTT clock start date for adult therapeutic circumcision? 13. Data Integrity Audits: Has the Trust conducted any internal audits or received any warnings from internal or external auditors regarding data quality issues or RTT clock start accuracy specifically within the Urology department in the last 24 months?
Date of Response: 20/07/2026
View Response: 11597.pdf
Freedom of Information Request Reference: 11596
Date Received: 17/06/2026
Summary:
1. Please provide the number of ECT treatments given to patients (if any) in the calendar years 2020, 2021, 2022, 2023, 2024 and 2025 2. Please provide the number of patients (if any) having received ECT treatment in the calendar years 2020, 2021, 2022, 2023, 2024 and 2025
Date of Response: 14/07/2026
View Response: 11596.pdf
Freedom of Information Request Reference: 11595
Date Received: 17/06/2026
Summary:
This is a freedom of information request relating to campaigns run by your trust involving nicotine, alcohol and digital well-being, and the spending on such in 2023, 2024 and 2025. Please provide me with the following information: 1. The total number of awareness or health promotion campaigns run by the trust primarily targeting: a) Nicotine, smoking, or vaping cessation/awareness. b) Alcohol consumption reduction or awareness. c) screen time or general digital well-being 2. Financial and Supplier Breakdown: a) The official name/title of any campaign. b) The total financial expenditure (specifying external marketing, advertising, or media spend where possible). If a campaign spanned multiple calendar years, please provide the breakdown by year. c) The names of any external PR firms, advertising agencies, or suppliers contracted to deliver or design the campaign. 3. Campaign Materials: a) Where available, please provide digital copies, internet links (URLs), or electronic versions of the promotional literature, artwork, videos, or materials used in these campaigns.
Date of Response: 14/07/2026
View Response: 11595.pdf
Freedom of Information Request Reference: 11594
Date Received: 16/06/2026
Summary:
Part A – Independent sector activity For each financial year 2021/22, 2022/23, 2023/24, 2024/25 and 2025/26 to date, please provide the following for any independent sector provider commissioned by NHS Lothian to deliver cataract surgery: a) Number of NHS-funded cataract procedures performed (per eye) b) Total expenditure (£) paid to the provider c) Mean unit price (£) paid per cataract procedure Part B – Insourcing arrangements For the same period, please confirm: a) Names of any insourcing providers used to deliver cataract surgery at NHS Lothian facilities b) Number of cataract procedures delivered by each provider c) Total expenditure (£) paid to each provider Part C – Procurement route For the providers identified above, please confirm: a) The procurement or contractual route used (e.g. NSS DPS, mini-competition, direct award, spot purchase or similar) b) Whether any further cataract outsourcing or insourcing procurement activity is currently planned or underway Part D – Cross-boundary patient flow For the same period, please provide: a) Number of NHS Lothian residents referred to NHS Golden Jubilee for cataract surgery b) Number of NHS Lothian residents referred to any other NHS Board for cataract surgery c) Number of patients from other NHS Boards treated for cataract surgery by NHS Lothian Part E – Internal context For the same period, please provide: a) Total number of cataract procedures performed by NHS Lothian at its own facilities b) Cataract waiting list size as at 31 March of each year c) NHS Lothian's current pathway for offering alternative provision where waits exceed the Treatment Time Guarantee
Date of Response: 10/07/2026
View Response: 11594.pdf
Freedom of Information Request Reference: 11593
Date Received: 16/06/2026
Summary:
To ask how many incidents have been reported by your staff members in relation to racial/racist/race related abuse, whether by patients or anyone else. If possible, could you disclose the nature of the report (verbal abuse, physical assault etc). Could this information be provided for 2021-2025.
Date of Response: 10/07/2026
View Response: 11593.pdf
Freedom of Information Request Reference: 11591
Date Received: 16/06/2026
Summary:
I wish to make a Freedom of Information Request for the dates & times the walk in GP clinic on Wester Hallies as not been open February the 11th.
Date of Response: 10/07/2026
View Response: 11591.pdf
Freedom of Information Request Reference: 11590
Date Received: 16/06/2026
Summary:
I am looking for the average number of available and occupied beds at the paediatric critical care unit at the Edinburgh Royal Infirmary for 2025.
Date of Response: 14/07/2026
View Response: 11590.pdf
Freedom of Information Request Reference: 11589
Date Received: 16/06/2026
Summary:
Q1. Do you provide autoantibody testing for diagnosis of Type 1 diabetes? Answer: Q1a. If yes, please indicate which assays are available either onsite or via referral to another laboratory: •GAD •IA-2 •ZnT8 •IAA Answer: Q1b. Does your organisation receive requests for Type 1 diabetes autoantibody testing in individuals without clinically diagnosed diabetes (e.g. screening of at-risk relatives or other asymptomatic individuals)? ☐ Yes ☐ No ☐ Unknown Q1c. Please provide the number of unique patients tested clinically for the following autoantibodies during: •Calendar year 2025 •January–March 2026 Please exclude research-only testing where identifiable. Please provide separate figures for: •onsite testing •outsourced/referred testing If exact patient numbers are not available, please provide the closest available measure (e.g. request numbers or assay volumes) and specify the metric used. Q1d. If an external laboratory is used, please provide: •laboratory/provider name •location Answer: Q2a. If readily available, please provide the number of unique patients in 2025 and Jan–Mar 2026 who tested positive for: i) one autoantibody ii) two or more autoantibodies Please exclude research-only testing where possible. Answer: Q2b. Of the unique patients who tested positive, how many were referred through an early stage/asymptomatic screening programme? Answer: Q3. Please provide the average turnaround time over the last 12 months for Type 1 diabetes autoantibody testing: •onsite testing •referred testing (if applicable) Answer:
Date of Response: 28/07/2026
View Response: 11589.pdf
Freedom of Information Request Reference: 11586
Date Received: 16/06/2026
Summary:
I would be grateful if you could provide the following information relating to laparoscopic cholecystectomy procedures performed within your Trust. 1. Procedure Volume a) How many laparoscopic cholecystectomy procedures were performed within your Trust during the most recently completed financial year? 2. Instrument Tray Composition a) Please provide the current instrument inventory list(s) for the standard laparoscopic cholecystectomy instrument tray(s) used within your Trust. b) If more than one laparoscopic cholecystectomy tray configuration is used within the Trust, please provide the inventory list for each version. c) Does the Trust use surgeon preference cards or procedure-specific pick lists for laparoscopic cholecystectomy? If yes, please provide any standard template used d) Please indicate whether the inventory lists supplied represent: • A standardised Trust-wide tray; • Site-specific trays; or • Consultant/surgeon-specific trays. 3. Tray Standardisation a) Does the Trust have a formal policy, guideline, or standard operating procedure relating to laparoscopic cholecystectomy instrument tray composition? If yes, please provide a copy. b) Has the Trust undertaken any review, rationalisation, optimisation, or redesign of laparoscopic cholecystectomy instrument trays within the last five years? If yes, please provide any reports, summaries, business cases, or recommendations that are held. 4. Reusable and Disposable Instrumentation a) Does the Trust routinely use reusable laparoscopic instruments for laparoscopic cholecystectomy? b) Does the Trust routinely use disposable single-use laparoscopic instruments for laparoscopic cholecystectomy? c) Please provide any existing inventory or documentation identifying which components are reusable and which are single-use. d) Does the Trust routinely use disposable/single-use ports or reusable ports? 5. Sterilisation and Tray Processing a) How many instrument trays or sterilisation containers are routinely opened for a standard laparoscopic cholecystectomy procedure? b) Are trays supplied in: • Reusable rigid sterilisation containers; • Sterile wrap systems; or • Both? 6. Sustainability Initiatives a) Has the Trust undertaken any sustainability-related initiative specifically relating to surgical instrument trays, reusable instrumentation, waste reduction, or operating theatre environmental impact within the last five years? If yes, please provide any reports, presentations, business cases, or policies held. 7. Photographic or Layout Documentation a) Does the Trust hold a tray map, instrument layout guide, tray photograph, or equivalent document for laparoscopic cholecystectomy trays? If yes, please provide a copy. 8. Sterilisation and Reprocessing Costs a) Does the Trust hold information on the cost of sterilisation, decontamination, reprocessing, or preparation of laparoscopic cholecystectomy instrument trays? If yes, please provide: • The most recent estimated cost per tray sterilisation/reprocessing cycle. • The methodology used to calculate this cost. • The date of the most recent calculation.
Date of Response: 10/07/2026
View Response: 11586.pdf
Freedom of Information Request Reference: 11530
Date Received: 25/05/2026
Summary:
Please provide copies of all policies, procedures, local guidelines, clinical pathways, protocols, or written instructions held by NHS Lothian that were in force at any time between the 1st of January 2022 and the present, and that relate to colorectal cancer care, specifically: 1. Screening and Referral for Colorectal Cancer: Policies or pathways relating to colorectal cancer screening, such as • Eligibility criteria for screening • Use of FIT (Faecal Immunochemical Test), stool tests, colonoscopy, sigmoidoscopy, CT colonography, or other screening investigations • Thresholds or criteria for urgent referral, further investigation, or repeat testing • Management of abnormal or borderline screening results 2. Referral pathways for suspected colorectal cancer, including: Criteria for urgent suspicion of cancer referral. including the below • Symptoms, blood test results, imaging findings, or FIT thresholds that trigger referral • Circumstances requiring escalation, urgent investigation, or specialist review. • Diagnosis and investigation 3. Guidelines relating to the diagnosis and investigation of colorectal cancer, including: • Recommended investigations for suspected colorectal cancer • Use and interpretation of FIT testing • Indications for colonoscopy, biopsy, imaging, or repeat investigations • Management of inconclusive, equivocal, or negative test results where suspicion remains 4. Treatment and Management of Colorectal Cancer: Clinical pathways, protocols, or guidance relating to treatment of colorectal cancer, including the below: • Surgical management • Chemotherapy, radiotherapy, immunotherapy, or palliative treatment pathways • Multidisciplinary team (MDT) decision-making processes • Follow-up, surveillance, and recurrence monitoring 5. Family History and Hereditary Cancer Risk: • Policies or guidance relating to assessment of family history of colorectal or related cancers • Criteria for identifying increased hereditary cancer risk • Referral pathways for genetic counselling or specialist review • Use of risk assessment tools or criteria relating to hereditary cancer syndromes 6. Genetic Testing and Screening: • Guidance relating to genetic screening or testing for hereditary colorectal cancer syndromes • Criteria or thresholds for offering genetic testing • Indications for testing for conditions such as Lynch syndrome, familial adenomatous polyposis (FAP), or other hereditary cancer syndromes • Circumstances in which tumour testing, germline testing, or family screening should be offered • Protocols relating to cascade testing or screening of relatives 7. Patient Information: Any patient-facing leaflets, written advice, consent documents, or informational materials relating to: • Colorectal cancer screening • Diagnostic investigations • Genetic testing or hereditary cancer assessment • Treatment options for colorectal cancer and follow-up care
Date of Response: 28/07/2026
View Response: 11530.pdf
Freedom of Information Request Reference: 11585
Date Received: 12/06/2026
Summary:
Please provide the following information in relation to the Lifelines project (lifelines.scot), including any predecessor or successor arrangements, from its inception to the present date: 1. The total funding received by Lifelines. 2. A breakdown of all funding received by Lifelines by financial year. 3. For each source of funding, please provide: o The name of the funding organisation. o The amount contributed. o The date(s) funding was provided. o The purpose or conditions attached to the funding, if any. 4. Copies of any funding agreements, grant awards, partnership agreements, memoranda of understanding, business cases, or other documents setting out financial contributions to Lifelines. 5. Details of any current or planned funding commitments to Lifelines. 6. Details of any income received from partner organisations, including but not limited to: o Scottish Ambulance Service o Scottish Government o Police Scotland o Scottish Fire and Rescue Service o Scottish Prison Service 7. The annual operating budget for Lifelines for each financial year since its establishment. 8. Details of expenditure incurred by Lifelines for each financial year, broken down by category where held (for example staffing, training, website development, administration, consultancy, or other costs).
Date of Response: 20/07/2026
View Response: 11585.pdf
Freedom of Information Request Reference: 11584
Date Received: 12/06/2026
Summary:
1. We request all documentation showing why the appointment of Professor Lamey as an NHS Consultant by NHS Lothian was deemed appropriate following an investigation into his conduct in Northern Ireland when he was reported to have failed to diagnose a significant number of patients, was struck off and was reinstated following appeal? 2. The reinstatement of Professor Lamey in relation to the above was under the condition that he worked under supervision. We would seek all records confirming the level of supervision Professor Lamey worked under during his tenure at NHS Lothian. 3. Professor Lamey was suspended from his role at NHS Lothian in 2024. We would request copies of all documents showing the reasons for this suspension.
Date of Response: 08/07/2026
View Response: 11584.pdf
Freedom of Information Request Reference: 11583
Date Received: 12/06/2026
Summary:
How many patients have been treated with the following drugs in the past 4 months: •Atogepant (Aquipta) – any disease •Erenumab (Aimovig) - any disease •Eptinezumab (Vyepti) – any disease •Fremanezumab (Ajovy) - any disease •Galcanezumab (Emgality) - any disease •Rimegepant (Vydura) – any disease •Botulinum Toxin (i.e., Botox, Dysport, Xeomin) - migraine ONLY
Date of Response: 10/07/2026
View Response: 11583.pdf
Freedom of Information Request Reference: 11582
Date Received: 12/06/2026
Summary:
I am writing to request information under the Freedom of Information (Scotland) Act 2002 regarding how your Health Board structures and delivers Child and Adolescent Mental Health Services (CAMHS) for children and young people with Learning Disabilities (LD). 1. Service Location & Organisational Structure For your CAMHS LD service, please provide: 1.1. The directorate / care group / service line the CAMHS LD service sits within (e.g., CAMHS, Neurodevelopmental Services, Specialist Children’s Services, Learning Disability Services, Mental Health & Learning Disability Directorate, etc.) 1.2. Whether CAMHS LD is delivered as: • A stand alone specialist CAMHS LD team • A sub team within core CAMHS • A joint service with paediatrics, community LD teams, or education • Another model (please specify) 2. Clinical Model & Pathways Please provide: 2.1. The clinical model(s) of care used (e.g., MDT assessment model, neurodevelopmental pathway, behavioural support model, systemic family model, trauma informed model, PBS, etc.) 2.2. Any eligibility criteria or referral criteria for CAMHS LD. 2.3. Whether the service provides: • Assessment only • Assessment + intervention • Consultation to other teams • Crisis support • Behavioural support • Medication management • Other functions (please specify) 2.4. Any written clinical pathways, flowcharts, or operational policies for CAMHS LD (please provide copies). 3. Workforce & MDT Composition Please provide: 3.1. The current MDT composition, including WTE for each role (e.g., psychiatry, psychology, nursing, OT, SLT, behavioural specialists, support workers, admin). 3.2. Whether the service has: • Dedicated consultant psychiatry input from CAMHS CCT Psychiatrists and/ or General LD Psychiatrists with CAHMS experience • Dedicated clinical psychology input • Access to LD nursing • Access to paediatricians • Access to social work or education liaison • Access to positive behaviour support (PBS) practitioners 3.3. Whether the service is co located with any other teams. 4. Governance & Clinical Oversight Please can you kindly provide: 4.1. The clinical governance structure for CAMHS LD (e.g., reporting lines, governance committees, clinical leads). 4.2. Whether the service participates in: • Local clinical governance meetings • Adverse event reviews • Audit programmes • Quality improvement programmes • National CAMHS or LD networks 5. Additional Documents Please can you kindly provide copies of any of the following, if available: • Service descriptions • Operational policies • Clinical pathways • Organisational charts • Job descriptions for CAMHS LD posts • Service improvement plans • Reports submitted to Board level governance
Date of Response: 10/07/2026
View Response: 11582.pdf
Freedom of Information Request Reference: 11581
Date Received: 11/06/2026
Summary:
Please provide copies of any recorded information held by NHS Lothian from January 1, 2024, to the present date regarding preparations, impact assessments, scoping exercises, or readiness reviews concerning proposed assisted dying legislation in Scotland or the wider UK (including, but not limited to, the Assisted Dying for Terminally Ill Adults (Scotland) Bill or the Terminally Ill Adults (End of Life) Bill). Specifically, I am requesting: 1. Impact Assessments & Scoping Exercises: Any documents, strategy papers, or reports detailing how potential changes to assisted dying laws would impact NHS Lothian services, including clinical pathways, palliative care, or post-death bereavement and spiritual care services. 2. Meeting Minutes & Briefings: Minutes of board meetings, committee meetings, or departmental briefings (including within the Spiritual Care and Bereavement Service) where preparations for, or the consequences of, assisted dying legislation were discussed. 3. Internal and External Correspondence: Any formal correspondence or briefing notes sent or received by senior health board management or service heads regarding the scoping of post-death family support or counseling requirements for families affected by a medically assisted death. If the board holds no recorded information on these points, please explicitly state that no scoping exercises or impact assessments have been carried out regarding this legislation to date.
Date of Response: 09/07/2026
View Response: 11581.pdf
Freedom of Information Request Reference: 11580
Date Received: 11/06/2026
Summary:
I would like to request the following information held by your trust: • How many doctors are on a SAS contract, broken down by medical specialty? • How many are doctors are on specialist doctor contracts, broken down by medical specialty? • How many doctors are on specialty doctor contracts, broken down by medical specialty? • How many doctors are on associate specialists, broken down by medical specialty? • How many doctors are on a staff grade contract, broken down by medical specialty? • How many doctors are employed in the Trust that are not in a formal training programme or on a SAS or consultant contract, broken down by medical specialty?
Date of Response: 14/07/2026
View Response: 11580.pdf
Freedom of Information Request Reference: 11579
Date Received: 11/06/2026
Summary:
I would be grateful if you could inform me, for the last three complete years, and for the current year to date, of the number of general medical services (GMS) contracts and primary medical services (PMS) agreements that your Board has entered into, and corresponding payments, broken down by reference to the contractor eligibility categories which are set out, respectively, in sections 17L(1) and 17CA(1) of the NHS (Scotland) Act 1978. In other words, for GMS contracts, I wish to be informed of how many are with 1. a medical practitioner 2. such other health care professional as may be prescribed 3. a qualifying partnership 4. a qualifying limited liability partnership, and 5. a qualifying company; plus corresponding payments plus corresponding payments. And for PMS agreements, I wish to be informed of how many are with 1. a medical practitioner 2. a health care professional (other than a medical practitioner) 3. a qualifying partnership 4. a qualifying limited liability partnership 5. a qualifying company, and 6. two or more of the persons mentioned in (1)-(5); plus corresponding payments. Similarly, where you provide or have provided over the same period primary medical services pursuant to section 2(1)(a), please provide me with the numbers of general practitioners and (if such be the case) of other healthcare professionals employed and/or engaged by you for that purpose, and the annual cost. If you have made arrangements over the same period to secure provision pursuant to section 2C(2) otherwise than by GMS contracts or PMS agreements, please provide me with the number of such arrangements and corresponding payments, along with the PMS eligibility categories within which all parties (save the Health Board) must fall in accordance with section 2C(2B).
Date of Response: 06/07/2026
View Response: 11579.pdf
Freedom of Information Request Reference: 11578
Date Received: 11/06/2026
Summary:
Could you please provide me with a copy of all documents, since April 1st 2024, circulated to or produced by members of the corporate management team related to the issue of separate sex workplace facilities.
Date of Response: 09/07/2026
View Response: 11578.pdf
Freedom of Information Request Reference: 11577
Date Received: 11/06/2026
Summary:
Please confirm whether your Health Board currently operates, hosts, commissions, contracts, or provides access to any medical laser or light-based service, including dermatology laser, birthmark or vascular laser, scar or burns laser, hair-removal laser, tattoo-removal laser, resurfacing laser, plastic surgery laser, paediatric laser, ophthalmology laser, photodynamic therapy, or other light-based treatment services. For each relevant service, please provide: 1. Service name 2. Hospital/site where the service is delivered 3. Specialty or department responsible for the service 4. Whether the service is NHS-funded, private, or mixed NHS/private 5. Type of laser or light-based equipment used 6. Manufacturer and model of each device, if held 7. Number of devices currently in use 8. Year each device was installed or first used, if held 9. Approximate annual treatment/procedure volume for each of the last three financial years 10. For each of the last three financial years, the total recorded income or revenue generated by the laser/light-based service, including NHS-funded, private patient, self-pay, insurer-funded, externally commissioned, contracted, insourced, outsourced, or third-party activity, where held.
Date of Response: 03/07/2026
View Response: 11577.pdf
Freedom of Information Request Reference: 11575
Date Received: 10/06/2026
Summary:
Please provide information for NHS Lothian on expenditure on aseptically prepared medicines sourced from the suppliers listed below, broken down by month and supplier, for the financial years specified. 1. Suppliers in scope Please include spend with the following suppliers, including any relevant trading-name, abbreviated-name, group-company or supplier-master variants used in your finance, pharmacy, procurement, homecare or accounts payable systems: • Quantum Pharmaceutical / Quantum Aseptics / Quantum Pharmaceutical Limited • Baxter Healthcare / Baxter Healthcare Limited • ITH Pharma / ITH Pharma Limited • Bath ASU / Pharmaxo / Qualasept Limited trading as Bath ASU • Fresenius Kabi / Fresenius Kabi Limited • B. Braun / BBraun / B. Braun Medical Limited • Lloyds Pharmacy Clinical Homecare / Lloyds Clinical / Lloyds Clinical Homecare If spend is recorded under a related trading name, historic name, parent company, group entity, supplier code or homecare-provider account but relates to one of the suppliers above, please include it and state the mapping used. 2. Products and services in scope For this request, “aseptically prepared medicines” means medicines supplied ready for administration that have been aseptically compounded or prepared by the supplier for the Board, whether patient-specific, batch-made, dose-banded or otherwise prepared aseptically. Please include, where applicable: • chemotherapy / SACT preparations; • monoclonal antibodies and other biologics prepared aseptically; • parenteral nutrition / TPN; • CIVAS / ready-to-administer injectable medicines; • antibiotic, antiviral, analgesic, PCA, palliative care or other infusion preparations; • aseptically prepared medicines supplied via homecare arrangements; • any other outsourced aseptically compounded injectable medicines. Please exclude spend that does not relate to aseptically prepared medicines, including standard licensed medicines supplied as ordinary stock, medical devices, consumables, pumps, giving sets, enteral nutrition, non-aseptic products, and general homecare delivery, dispensing, nursing or support fees, unless those costs are inseparable from the aseptic medicine supply in your records. If your systems cannot fully isolate aseptically prepared medicine spend from wider supplier or homecare-provider spend, please provide the closest available measure and explain what is included and excluded. 3. Time periods Please provide the data by calendar month for the following financial years: • FY2023/24: 1 April 2023 to 31 March 2024 • FY2024/25: 1 April 2024 to 31 March 2025 • FY2025/26: 1 April 2025 to 31 March 2026 If your Board uses different shorthand labels such as FY24, FY25 or FY26, please use the date ranges above. 5. Accounting basis and caveats Please state: 1. whether the figures are net or gross of VAT; 2. whether credit notes, rebates, retrospective adjustments or recharges are included; 3. whether the figures are based on invoice date, payment date, accounting period, purchase order date, homecare recharge date or another basis; 4. whether the figures include direct purchases only, or also purchases made through shared procurement, regional procurement, framework arrangements, homecare arrangements, recharges or centrally managed arrangements where the Board ultimately incurred the cost; 5. whether any relevant spend is held by another body, such as National Procurement, NHS National Services Scotland, Public Services Delivery Scotland, a regional procurement hub, another NHS Board, or a homecare management service. I am not requesting patient-level information, prescription-level information, product-level unit prices, individual invoice copies, contract documents, commercially confidential pricing schedules, or any personal data. Aggregated monthly supplier spend is sufficient. 6. If the full request exceeds the cost limit If you consider that the full request would exceed the applicable cost limit, please provide advice and assistance on how it may be narrowed. In that event, please consider the following narrower versions in order of preference: 1. monthly spend by supplier only, without product/service category; 2. annual spend by supplier for each financial year; 3. spend for FY2024/25 and FY2025/26 only; 4. total spend across all listed suppliers by month; 5. confirmation of whether the data is held and which system, department or external body holds it.
Date of Response: 23/07/2026
View Response: 11575.pdf
Freedom of Information Request Reference: 11571
Date Received: 09/06/2026
Summary:
I would like to request information on how much Annual leave is lost from staff members on NHS Lothians staff bank without actually taking the accrued annual leave hours they are entitled to after completing shifts with the staff bank.
Date of Response: 06/07/2026
View Response: 11571.pdf
Freedom of Information Request Reference: 11570
Date Received: 09/06/2026
Summary:
1. Please provide the initial date on which NHS Lothian Women's and Children's Services formally commenced, or otherwise internally initiated, the service review of continuing care respite services for Sunndach and Calareidh. 2. For each year since the initiation of the service review., please provide details of the total project costs incurred by NHS Lothian in relation to the service review. This should include all directly attributable project costs, Including staffing time specifically assigned to the review, consultancy, legal or advisory costs (if applicable), and any associated expenses. Please exclude ongoing service delivery costs unrelated to the service review project and present costs on a year-by-year basis.
Date of Response: 06/07/2026
View Response: 11570.pdf
Freedom of Information Request Reference: 11569
Date Received: 09/06/2026
Summary:
1. Please provide the number of individual families or service packages supported by the NHS Lothian RHCYP Outreach Service in each year from 2016 to 2026 inclusive. Where relevant, please include the definition used for counting ‘families or 'packages’. 2. Please provide full details of the current eligibility criteria that a child must meet in order to qualify for a supporting care package from the NHS Lothian RHCYP Outreach Service. In addition, please provide details of any changes made to these eligibility criteria since 2016 to 2026 inclusive, including the nature of each change, the reason for the change and the date on which it was implemented.
Date of Response: 07/07/2026
View Response: 11569.pdf
Freedom of Information Request Reference: 11568
Date Received: 08/06/2026
Summary:
Q1. How many patients have been treated in the past 3 months with the following agents for renal cell carcinoma (any stage): •Avelumab + Axitinib •Axitinib •Cabozantinib •Everolimus •Lenvatinib + Everolimus •Lenvatinib + Pembrolizumab •Nivolumab monotherapy •Nivolumab + Cabozantinib •Nivolumab + Ipilimumab •Pazopanib •Pembrolizumab monotherapy •Pembrolizumab + Axitinib •Radiotherapy only •Sunitinib •Temsirolimus •Tivozanib •Other active systemic anti-cancer therapy •Palliative care only •Pembrolizumab (solution for subcutaneous injection) Q2.In the past three months, how many advanced renal cell carcinoma patients received the following first-line treatments : •Avelumab + Axitinib (Bavencio + Inlyta) •Cabozantinib (Cometriq) •Nivolumab (Opdivo) •Nivolumab + Cabozantinib (Opdivo + Cometriq) •Nivolumab + Ipilimumab (Opdivo + Yervoy) •Lenvatinib + Pembrolizumab (Kisplyx + Keytruda) •Pembrolizumab + Axitinib Q3. In the last 3 months, how many patients have been initiated* on the following agents for treatment for Renal Cell Carcinoma? : •Nivolumab (monotherapy) •Nivolumab + Ipilimumab •Nivolumab + Cabozantinib •Avelumab + Axitinib •Lenvatinib + Everolimus •Lenvatinib + Pembrolizumab (Kisplyx + Keytruda) •Cabozantinib (Cometriq) •Pembrolizumab + Axitinib Q4. In the last 3 months, how many patients have undergone full or partial nephrectomy (any of the following OPCS codes M02.1, M02.2, M02.3,M02.4, M02.5, M03.1, M03.9, M04.2, M10.1 or M10.4)? Q5. Does your trust participate in any clinical trials for the treatment of renal cell carcinoma? If so please provide the name of each trial and number of patients that are taking part?
Date of Response: 06/07/2026
View Response: 11568.pdf
Freedom of Information Request Reference: 11566
Date Received: 04/06/2026
Summary:
I am requesting, for each of the financial years 2021-22, 2022-23, 2023-24, 2024-25 and 2025-26: 1. How many patients were receiving Diabetes treatment consumables, including insulin pump therapy and continuous glucose monitoring? 2. In each of those years, how many patients had their provision of Diabetes treatment consumables discontinued or suspended? If possible, please break this down by reason, including but not limited to: clinical decision, patient choice, equipment failure, funding/budget constraints, consumables supply issues, or transition to a different therapy. 3. What is the total spend by NHS Lothian on Diabetes treatment consumables in each of the financial years? 4. How many patients are currently on a waiting list or have been assessed as clinically eligible for Diabetes treatment consumables but have not yet received them, as of the most recent date for which data is available?
Date of Response: 06/07/2026
View Response: 11566.pdf
Freedom of Information Request Reference: 11565
Date Received: 04/06/2026
Summary:
I acknowledge NHS Lothian's position that requests for an individual's own personal data should ordinarily be considered under the Data Protection Act 2018 rather than the Freedom of Information (Scotland) Act 2002 (FOISA). However, I am concerned that my request may have been characterised too broadly as a request solely for personal information. Classification of the Request While aspects of my request undoubtedly relate to my personal data, my request was not limited to obtaining copies of information about myself. It also sought information concerning the processing, sharing, governance, systems, repositories, recipients and organisational arrangements associated with that processing. The response states that the request has been passed to the Data Protection Team and that the information requested is personal to myself and therefore exempt under section 38 FOISA. However, the response does not explain whether the individual elements of the request were assessed separately, nor whether any part of the request was considered to fall within FOISA as recorded organisational information rather than personal data. Organisational Information and FOISA Scope Please review whether any part of the request sought recorded information concerning: • information-sharing arrangements; • governance structures; • audit processes; • recipient organisations; • data processors; • system suppliers; • case management systems; • repositories; • policies, procedures or operational arrangements relating to the handling of information. To the extent that such information exists, please consider whether it should properly be considered under FOISA rather than being treated solely as a Subject Access Request. Application of Section 38 FOISA If NHS Lothian's position is that every element of the request is exempt under section 38 FOISA, please identify which specific parts of the request were assessed and explain why each element was considered to constitute my personal data rather than organisational information held by NHS Lothian. Transfer to the Data Protection Team Please clarify whether any part of my request relating to information-sharing arrangements, audit records, recipient organisations, processors, system suppliers, repositories, case management platforms or governance arrangements remained within the FOI process, or whether all elements were transferred to the Data Protection Team. If all elements were transferred, please explain the basis upon which NHS Lothian concluded that no part of the request sought recorded organisational information falling within the scope of FOISA. Decision-Making Framework Please identify the basis upon which NHS Lothian concluded that the request fell wholly within the scope of the Data Protection Act 2018 rather than, in whole or in part, within the scope of FOISA. This should include any criteria, guidance, policy, procedure or assessment framework relied upon in reaching that conclusion. If a recorded assessment exists documenting that decision, please advise whether it can be provided.
Date of Response: 02/07/2026
View Response: 11565.pdf
Freedom of Information Request Reference: 11564
Date Received: 08/06/2026
Summary:
Please provide the requested information in table format as follows: Rows (time periods): 1996–2005 2006–2015 2016–2025 Columns: 0–5 years after infection 5–10 years after infection 10–20 years after infection Over 20 years after infection
Date of Response: 01/07/2026
View Response: 11564.pdf
Freedom of Information Request Reference: 11563
Date Received: 08/06/2026
Summary:
I would like to please request the following information relating to smoking enforcement on or around hospital grounds. Please provide the following information for each of your hospitals for each of the calendar years from 2022 to 2025. 1. How many fixed penalty notices (FPNs) related to smoking on or near hospital grounds have been issued by your organisation? 2. What was the total monetary value of these fines? 3. How many of these fines remain unpaid (if recorded)? 4. How many formal warnings relating to smoking on or near hospital grounds were issued? 5. What is the current policy regarding smoking on or near hospital grounds within your NHS Board / Trust / local authority area? 6. How many formal complaints has your NHS Board / Trust received? 7. Does your organisation enforce a smoke-free perimeter or exclusion zone around hospital entrances or buildings? If yes: What is the required distance? When was the policy introduced?
Date of Response: 06/07/2026
View Response: 11563.pdf
Freedom of Information Request Reference: 11560
Date Received: 08/06/2026
Summary:
I am requesting a copy of the Standard Operating Procedure (SOP) or written policy governing how NHS Lothian transfers information and patient data to the Scottish Public Services Ombudsman (SPSO). I require the recorded information or technical specifications that clarify the following operational details: 1. Which specific role, title, or department within NHS Lothian holds the administrative responsibility for extracting electronic health records from internal systems and uploading them to the Objective Connect workspace? 2. What recorded internal verification protocol, check-list, or audit mechanism is mandated to ensure that the files uploaded to Objective Connect represent a complete, unaltered technical record (including systemic metadata) rather than a selective subset?
Date of Response: 06/07/2026
View Response: 11560.pdf
Freedom of Information Request Reference: 11559
Date Received: 05/06/2026
Summary:
How many Maternity patients were treated for Gestational Diabetes Mellitus (GDM) in the 12 month period? Do you have a digital product to support the treatment of patients with GDM? If you have a digital product, can you supply the total contract value and duration? How many type 1 diabetes patients (all adults & paediatrics) do you care for in your hospitals? How many type 2 diabetes patients (all adults & paediatrics) specifically on insulin do you care for in your hospitals?
Date of Response: 02/07/2026
View Response: 11559.pdf
Freedom of Information Request Reference: 11552
Date Received: 03/06/2026
Summary:
I would be grateful to receive a copy of any guidance your health board holds and/or has provided to maternity teams for supporting births where the pregnancy is as a result of a surrogacy arrangement.
Date of Response: 01/07/2026
View Response: 11552.pdf
Freedom of Information Request Reference: 11549
Date Received: 02/06/2026
Summary:
A copy of all educational literature resources (e.g. Word documents, powerpoints, Patient Information Leaflets, written Advice and Guidance documents etc.) that are distributed, or presented, to patients within your Trust relating to the management of Hypertension (High Blood Pressure), either in community-based or hospital-based settings.
Date of Response: 21/07/2026
View Response: 11549.pdf
Freedom of Information Request Reference: 11535
Date Received: 28/05/2026
Summary:
How many times have mental health hospitals in your health board been running at 100% occupancy, broken down by month in each of the last three calendar years, including the most up to date data you have for this year?
Date of Response: 06/07/2026
View Response: 11535.pdf
Freedom of Information Request Reference: 11525
Date Received: 21/05/2026
Summary:
I am requesting information held by your Trust relating to the diagnosis, management and support of patients with Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome. Please provide the following information, where held: 1. Clinical pathways and diagnosis Please provide copies of any clinical guidelines, protocols, or care pathways relating to: • Diagnosis of MRKH syndrome • Investigation of suspected Müllerian anomalies or congenital absence of uterus and/or vagina • Referral pathways into specialist gynaecology or tertiary services for MRKH If recorded and readily accessible, please also provide: • Average time from referral to confirmed diagnosis of MRKH • Typical number of appointments prior to diagnosis 2. Multidisciplinary care Please provide details of MRKH management within your Trust, including: • Whether care is delivered via a multidisciplinary team (MDT) • Professional groups involved (e.g. gynaecology, nursing, psychology, psychosexual therapy, endocrinology) • Whether psychological support is routinely offered at or shortly after diagnosis • Any written guidance regarding timing or referral to psychological support • Whether formal MDT review processes exist for MRKH patients 3. Psychological and supportive care Please provide information on: • Availability of psychological support services for MRKH patients • Availability or referral pathways for psychosexual therapy or sexual wellbeing support • Waiting times for psychological or psychosexual support (if recorded) 4. Trauma-informed care and communication Please provide any policies, guidance, or training materials relating to: • Trauma-informed care in gynaecology or reproductive health services • Communication of sensitive diagnoses (including MRKH) • Breaking bad news in gynaecology or reproductive health contexts • Consent and safeguarding procedures for intimate examinations in these services Additionally, please confirm: • Whether trauma-informed care training is provided to relevant staff • Whether such training is mandatory, recommended, or audited 5. Patient information materials Please provide copies of any patient information materials provided to MRKH patients, including: • Diagnostic information leaflets • Information on management options, including non-surgical vaginal dilator therapy (where applicable) • Fertility counselling information • Sexual health, intimacy, or relationship support materials (if available) 6. Service activity data (last 3 years available) If recorded and held in a retrievable format, please provide: • Number of patients diagnosed with MRKH • Number of MRKH patients referred for psychological support • Number of MRKH patients referred for psychosexual therapy (if applicable) 7. Vaginal dilator support services Please confirm: • Which service provides information and support regarding non-surgical vaginal dilator therapy (e.g. gynaecology, pelvic health physiotherapy, or other service) • Whether written patient guidance or materials are used to support this process
Date of Response: 20/07/2026
View Response: 11525.pdf
Freedom of Information Request Reference: 11501
Date Received: 18/05/2026
Summary:
I would like to request the following information for the period from 1 April 2020 to the date this request is processed, broken down by financial year where possible: 1. The number of patients removed from elective treatment or surgery waiting lists because they were recorded as unavailable for treatment. 2. The number of patients removed from gynaecology waiting lists because they were recorded as unavailable for treatment. 3. The number of complaints received relating to: • removal from waiting lists • communication surrounding waiting list removals • delays linked to pregnancy, where recorded 4. Copies of any current guidance, policies or standard operating procedures relating to patients who become pregnant while on an elective waiting list. 5. Copies of any standard letters or patient communications used to notify patients they have been removed from a waiting list. 6. Copies of any Equality Impact Assessments or formal reviews concerning the impact of waiting list management policies on women or pregnant patients.
Date of Response: 10/07/2026
View Response: 11501.pdf
Freedom of Information Request Reference: 11442
Date Received: 28/04/2026
Summary:
Please provide the following information for the past five years: Engagement of Independent Providers a) A list of all independent/private organisations commissioned, contracted, or otherwise engaged to deliver: Psychological therapy services ADHD assessment and/or treatment services Autism assessment services b) For each organisation identified, please provide: The name of the organisation The type of services delivered The start and end date of the arrangement (or confirmation if ongoing) Nature of the Arrangement For each provider listed, please specify: The mechanism of engagement (e.g. formal contract, service level agreement, framework agreement, direct award, spot purchasing, individual patient funding, pilot programme, or other) Whether the arrangement was established via a competitive tender process, framework agreement, or non-competitive route If non-competitive, the rationale for this approach (where recorded) Contractual and Financial Information For each arrangement, please provide: The total contract value, or total spend to date (annual breakdown if available) The duration of the agreement Any available high-level description of pricing structure (e.g. per-assessment, block contract, per-session rate), where not exempt under Section 33 Activity and Service Use Where available, please provide: The number of referrals made to each provider The type of patients referred (e.g. adult, CAMHS, complex cases, waiting list initiatives) Whether these services were used as part of a waiting list reduction initiative or service pressure response Governance and Decision-Making a) Please outline the internal process by which independent providers are approved or engaged within your organisation b) Please provide the job titles (not individual names) of the roles responsible for: Commissioning or approving such arrangements Managing relationships with independent providers Overseeing clinical governance of outsourced services c) Where possible, please provide generic contact routes (e.g. departmental email addresses) for these functions Supporting Documentation Please provide copies of, or links to: Any service specifications, agreements, or memoranda of understanding with independent providers (redacted as appropriate) Any internal policies or guidance relating to the use of independent providers for these services Any documentation relating to pilot programmes or waiting list initiatives involving external providers Additional Context If available, please provide: Any evaluation, audit, or outcome data relating to the use of independent providers Any stated future plans to expand, reduce, or change the use of independent providers for these services
Date of Response: 26/06/2026
View Response: 11442.pdf
Freedom of Information Request Reference: 11419
Date Received: 23/04/2026
Summary:
How many people were ahead of me on the waiting list on the day I joined it? On average, how many patients undergo the routine procedure every week? As of today, or the day on which you answer my questions, or the nearest practicable date, how many people were ahead of me on the routine list?
Date of Response: 25/05/2026
View Response: 11419.pdf
Carer Positive Icon
Awards Aware Icon
We are a Living wage Employer Icon
Duke of Edinburgh's Award Logo
Young Person's Guaranteed Employer Logo
Scottish Top Employers Logo
Disability Confident Employer Logo
 
CONTACT NHS LOTHIAN
Lothian NHS Board
Waverley Court
4 East Market Street
Edinburgh
EH8 8BG

Main Switchboard: 0131 242 1000
YOUR RIGHTS
OUR VALUES INTO ACTION
Around 3,000 colleagues across NHS Lothian have developed Our Values, a set of common values and ways of working - to the benefit of everyone working in the organisation and, most importantly - to the benefit of our patients.
WORKING WITH NHS LOTHIAN
MEDIA ENQUIRIES
STAY CONNECTED TO NHS LOTHIAN
Facebook
Twitter
YouTube
Vimeo
Instagram
PARTNERS
NHS Lothian Charity Logo
Tel: +44 (0)131 465 5850
Email: loth.charity@nhs.scot

Scottish Registered Charity No: SC007342
The official charity of NHS Lothian.
From the everyday to the transformational, we support NHS Lothian to excel for all the communities it serves: patients, families, carers and staff.
Making healthcare better, together.
Find out more about NHS Lothian Charity
Donate